Biodesix Highlights at the CHEST Annual Meeting
LOUISVILLE, Colo. — Biodesix, Inc. (Nasdaq: BDSX), a frontrunner in diagnostic solutions, is excited to present vital findings and engage in educational forums at the CHEST Annual Meeting, taking place in the vibrant city of Chicago. This event, which spans several days, will feature groundbreaking research and updates crucial for professionals in the lung health space.
Presentations That Matter
Among the significant highlights is the presentation detailing preliminary findings from the CLARIFY study. This analysis is set to take place in a specially convened Learning Theater session.
The Key Presentation
With the title, Driving to a New Standard of Care in Lung Nodule Management: Preliminary Results from the Nodify Lung Real-World CLARIFY Study, Biodesix’s own Michael Kammer, PhD, who is also the Head of Radiomics, will lead the discussion. Attendees can catch this enlightening presentation on October 21 at 2:00 PM CDT in Learning Theater 4.
This session aims to shed light on the outcomes from the first thousand patients involved in the CLARIFY study. Designed as a progressive initiative, the CLARIFY study focuses on validating the effectiveness of the Nodify CDT and Nodify XL2 tests across varied patient demographics through a meticulous review of clinical data.
Lung Nodule Management Insights
Another insightful presentation will delve into a national analysis concerning the management of lung nodules. This segment will disclose why adopting a standardized approach to lung nodule management is vital for both enhancing healthcare resource deployment and elevating patient treatment outcomes.
Healthcare Resource Utilization
This discussion, lead by Kimberly Le, PharmD, MS, MBA, Director of Health Economics Outcomes Research at Biodesix, will address Pulmonary Nodule-related Healthcare Resource Utilization After Diagnosis of Pulmonary Nodule in the United States. It’s slated for October 22, at 10:20 AM, promising critical insights for attendees.
Independent Presentations by Industry Experts
The CHEST Annual Meeting will also feature a variety of independent presentations conducted by healthcare professionals showcasing the clinical relevance of Biodesix's Nodify lung tests within diverse patient groups.
Exploring Clinical Efficacy
One notable presentation is titled Comparison of the Blood-based Nodify XL2 Test with PET/CT to Evaluate for Malignancy in Indeterminate Pulmonary Nodules in an Endemic Fungal Region, presented by Michael Torres Lizardi, MD, scheduled for October 19 at 11:20 AM CDT. This discussion will explore innovative approaches in evaluating pulmonary nodules.
Additionally, Elizabeth Samper Perez will speak on the Impact of the Nodify Lung Test Strategy in the Risk Stratification of Lung Nodules, expected to offer a poignant look into how these tests influence lung nodule assessment in a Miami-based practice. This takes place on October 22 at 10:20 AM CDT.
Further enlightening sessions include a retrospective analysis led by Kevin Huynh, DO, focusing on the role of Biodesix biomarkers in enhancing risk assessment and reducing invasive procedures related to solitary pulmonary nodules.
Engagement Opportunities at the Event
Attendees should also make time to visit Biodesix’s booth #1012, where executives and medical officers will be available for discussions on the evolving landscape of lung health diagnostics and the innovative role of biomarkers in lung nodule management.
Scott Hutton, the CEO of Biodesix, expressed his enthusiasm, stating, "This is indeed a pivotal moment in the lung diagnostics field, especially with the convergence of experts during the CHEST Annual Meeting. The presentation of cutting-edge research and insights correlates perfectly with Lung Cancer Awareness Month starting soon after the conference."
About Biodesix
Biodesix has proven to be a leader in diagnostic solutions, with a clear mission: to enhance clinical care and improve patient outcomes. Their groundbreaking tests, including the Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, serve as pivotal tools in personalized patient care. Further, Biodesix extends its capabilities through Biodesix Development Services, collaborating with biopharmaceutical and research institutions to advance diagnostic technologies and therapeutic developments.
Biodesix Contacts
Media Inquiries
Natalie St. Denis, Director Corporate Communications, Biodesix
Email: natalie.stdenis@biodesix.com
Phone: (720) 925-9285
Investor Relations
Chris Brinzey, Partner, ICR
Email: chris.brinzey@icrhealthcare.com
Phone: (339) 970-2843
Frequently Asked Questions
What is the primary focus of the CHEST Annual Meeting?
The CHEST Annual Meeting emphasizes advancements in lung health, showcasing research and innovations in lung care and diagnostics.
Who will present at Biodesix's session?
Michael Kammer, PhD, is set to discuss significant findings from the CLARIFY study.
What are the Nodify tests?
Nodify tests are diagnostic tools that help assess lung nodule risks and guide cancer treatment decisions.
How is Biodesix contributing to lung health diagnostics?
Biodesix aims to enhance patient outcomes by providing innovative diagnostic solutions and collaborating with healthcare professionals.
Where can I learn more about Biodesix?
To find out more, visit Biodesix's website at biodesix.com for further details about their services and offerings.
